The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice
- Author:
Geoffrey HACKETT
1
;
Michael KIRBY
;
Rowland W. REES
;
T. Hugh JONES
;
Asif MUNEER
;
Mark LIVINGSTON
;
Nick OSSEI-GERNING
;
Janine DAVID
;
Jeff FOSTER
;
Philip A. KALRA
;
Sudarshan RAMACHANDRAN
Author Information
- Publication Type:Review Article
- From:The World Journal of Men's Health 2023;41(3):508-537
- CountryRepublic of Korea
- Language:English
- Abstract: Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. A multi-disciplinary panel from BSSM reviewed the available literature on TD and provide evidence-based statements for clinical practice. Evidence was derived from Medline, EMBASE and Cochrane searches on hypogonadism, testosterone therapy (T Therapy) and cardiovascular safety from May 2017 to September 2022. This revealed 1,714 articles, including 52 clinical trials and 32 placebo-controlled randomised controlled trials. A total of twenty-five statements are provided, relating to five key areas: screening, diagnosis, initiating T Therapy, benefits and risks of T Therapy, and follow-up. Seven statements are supported by level 1 evidence, eight by level 2, five by level 3, and five by level 4. Recent studies have demonstrated that low levels of testosterone in men are associated with increased risk of incident type 2 diabetes mellitus, worse outcomes in chronic kidney disease and COVID 19 infection with increased all-cause mortality, along with significant quality of life implications. These guidelines should help practitioners to effectively diagnose and manage primary and age-related TD.
